Loading
Life sciences · Journal article
Arta Medica · October 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Objectives. Bee venom and its major peptide melittin can disrupt cell membranes and alter several cancer-related pathways, but systemic toxicity and the absence of clinical efficacy data limit translation. This review evaluated the cellular targets, preclinical evidence, delivery strategies, safety concerns, and requirements for clinical development. Methods. A structured narrative review searched Google Scholar, PubMed Central, relevant publisher platforms and Moldovan national repositories for English-language publications available through July 6, 2026. Priority was given to mechanistic studies, normal-cell comparators, animal tumor models, targeted-delivery investigations, and clinical evidence. Results. In preclinical models, melittin modifies tumor-cell membranes and growth-factor receptor organization; activates mitochondrial and death-receptor-mediated apoptosis; and affects phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K)/AKT/mTOR, mitogen-activated protein kinase (MAPK), Janus kinase/signal transducer and activator of transcription (JAK/STAT), nuclear factor kappa B (NF-κB), autophagy, mitophagy, endoplasmic reticulum stress, and ferroptosis-related processes. Studies also report reduced cell-cycle progression, migration, invasion, and angiogenesis, together with improved responses to selected anticancer agents. Nanocarriers reduce direct erythrocyte exposure and improve tumor delivery in animal models, but clinical antitumor benefit has not been established. No approved melittin-based anticancer therapy was identified. Conclusions. Bee venom and melittin represent sources of bioactive compounds for anticancer drug development. However, their therapeutic potential remains preclinical, and current evidence does not support their use as alternatives to established cancer treatments. Further progress requires standardized preparations, pathway-specific validation, comparative safety studies, pharmacokinetic assessment, reproducible manufacturing, and controlled clinical trials.